Background: OMICRON, a SARS-COV-2 strain, has generated global concern. This brief article discusses the discovery and dissemination of, which spurred hypotheses about omicron's genesis and infectious responsibility. Mutant strain in spike protein's RBD region exceeds vaccine immunity, causing worry. The next part discusses transmission, infectivity, morbidity, and COVID-19 immunisation. Classification: WHO and TAG-VE suggested viral evolution on November 26, 2021. They called B.1.1.529 omicron. This finding was based on TAG-VE data showing that Omicron has various alterations that affect how it acts, such as how easy it spreads or the severity of the disease it caused. Symptoms: The unique COVID variation "Omicron" caused high fever, sputum, fatigue, and loss of taste and smell. Transmission: How Omicron was more transmissible than Delta is unclear. In Africa, where this variation is prevalent, more persons are positive. Epidemiological research will identify whether this is related to Omicron or other variables. Severity: Due to improved population immunity and lower severity of intrinsic Omicron infections, the Omicron outbreak will likely have a lower impact on people's health than prior covid-19 waves. In South Africa's predominantly youthful population, 21% were hospitalised with SARS-CoV-2 Omicron. Patients with catastrophic clinical outcomes might rise during epidemics in communities with numerous enumerations and lower disease levels or give vaccination protection. Milder symptoms in South Africa following omicron versus delta infection are comforting. Omicron strain breakouts won't have little health effects elsewhere. Treatment: Remdesivir, Molnupiravir, and Paxlovid (not yet available in India) are suggested in the early stages of a viral infection. This prevents the illness from developing. Conclusion: Most therapeutic antibodies licenced to treat covid-19 are ineffective in the Omicron variant, according to the research.